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Streszczenie
Wstęp: Zwężenie zastawki aortalnej to najczęstsza nabyta 
wada zastawkowa serca. U pacjentów z małym pierścieniem 
aortalnym, po operacji wymiany zastawki aortalnej na zastaw-
kę sztuczną może wystąpić zjawisko tak zwanego niedopaso-
wania rozmiaru zastawki do pacjenta (ang. patient-prosthesis 
mismatch – PPM), co może prowadzić do zwiększenia gradien-
tu przezzastawkowego i mniejszej redukcji przerostu lewej 
komory. Zjawisko PPM jest rozpoznawane u chorych z indek-
sowaną efektywną powierzchnią ujścia (ang. indexed effective 
orifice area – iEOA) < 0,85 cm2/m2. 
Celem pracy była ocena częstości występowania zjawiska PPM 
w zależności od rozmiaru implantowanej zastawki u pacjentów 
poddanych operacji wymiany zastawki aortalnej oraz około­
operacyjna ocena wyników leczenia. 
Materiał i metody: Badana grupa obejmowała 92 pacjen-
tów w wieku 21–74 lata, u których wszczepiono mechaniczne 
zastawki St. Jude Medical. Oceniano częstość powikłań oraz 
parametry echokardiograficzne. Chorych podzielono na trzy 
grupy. Pierwsza obejmowała 15 pacjentów, u których wszcze-
piono zastawki o małym pierścieniu (17 mm i 19 mm), druga 
56 chorych z zastawkami o średnim rozmiarze (21 mm i 23 mm), 
a trzecia 21 pacjentów z zastawkami o dużym rozmiarze (25 mm, 
27 mm i 29 mm). 
Wyniki: W pierwszej grupie PPM rozpoznano u wszystkich, 
w drugiej u 92,9%, a w trzeciej u 52% chorych. Śmiertelność 
okołooperacyjna wśród wszystkich osób poddanych operacji 
wyniosła 5,4%. Gradient przez zastawkę aortalną u pacjentów 
z małą zastawką wyniósł średnio 20,25 mm Hg, u chorych ze 
średnią zastawką 13,42 mm Hg, a u pacjentów z dużą zastaw-
ką 11 mm Hg.
Słowa kluczowe: stenoza aortalna, PPM, leczenie operacyjne.
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Abstract
Background: Aortic stenosis is the most common acquired val-
vular heart disease. In some patients with small aortic annuli, 
after the surgical implantation of the artificial aortic valve, pa-
tient­prosthesis mismatch (PPM) may be observed. It can lead 
to an increased transvalvular gradient and decreased reduc-
tion of left ventricular hypertrophy. PPM is detected in patients 
with iEOA < 0.85 cm2/m2. 
The aim of the study was the evaluation of PPM incidence in 
relation to the size of the prosthetic valves implanted in pa-
tients undergoing aortic valve replacement, as well as the peri-
operative assessment of treatment results of PPM patients. 
Material and methods: The study population included 92 pa-
tients, aged between 21 and 74 years old, who were implanted 
with St. Jude Medical mechanical aortic valves. The rate of 
complications and the echocardiographic parameters were 
evaluated. Patients were divided into three groups. The first 
study group consisted of 15 patients who underwent aortic 
valve implantation and received valves of small aortic an-
nulus diameter (17 mm, 19 mm), the second group included 
56 pa tients who received medium-sized valves (21 mm, 23 mm), 
and the third one consisted of 21 patients who were implanted 
with valves of large aortic annulus diameter (25 mm, 27 mm, 
29 mm). 
Results: In the first group, PPM was diagnosed in all patients, 
in the second group in 92.9%, and in the third group in 52%. 
Perioperative mortality was 5.4%. Average transvalvular gradi-
ent in patients with small prostheses was 20.25 mm Hg, in pa-
tients with medium prostheses 13.42 mm Hg, and in patients 
with large prostheses 11 mm Hg.
Key words: aortic stenosis, PPM, surgical treatment.
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Introduction
Aortic valve stenosis is one of the most frequent diseas-
es of the cardiovascular system encountered by surgeons 
during the course of their work. In recent years, the number 
of aortic valve implantation procedures has risen progres-
sively in comparison to the decreasing number of coronary 
interventions.
In patients with small aortic annuli, after the aortic 
valve is replaced with a prosthetic valve, the phenomenon 
of patient­prosthesis mismatch (PPM) may occur. It may 
negatively affect hemodynamic parameters, result in trans-
valvular gradient increase, and prevent the reduction of left 
ventricular hypertrophy despite the normal functioning of 
the valve [1­3]. Consequently, this may lead to increased 
early and long-term mortality among the operated patients 
[4]. PPM is not a common problem, but, according to some 
studies, it may occur in as many as 70% of patients under-
going aortic valve replacement [5].
According to the original definition by Rahimtoola [6], 
PPM occurs when ‘the effective prosthetic valve area, af-
ter insertion into the patient, is less than that of a normal 
human valve’. This stems from the fact that the implanted 
valve is placed intra-aortically and is equipped with its 
own annulus, which significantly reduces the diameter of 
the valve orifice area after implantation [7, 8]. It is currently 
believed that the problem pertains to patients with indexed 
effective orifice area (iEOA) < 0.85 cm2/m2 [5, 9]. 
Depending on the iEOA value, PPM is considered to 
be moderate for 0.65 cm2/m2 < iEOA ≤ 0.85 cm2/m2 and 
severe for iEOA ≤ 0.65 cm2/m2. In different studies, iEOA 
> 0.85 cm2/m2 is considered either as mild PPM or insignifi-
cant PPM [10­12].
The data above indicate that surgeons can directly in-
fluence the improvement of the iEOA value by selecting 
appropriate prosthetic valves, which consequently leads to 
the improvement of hemodynamic parameters and helps 
avoid PPM [13­15]. 
Selecting prosthetic valves of appropriate sizes is par-
ticularly important in the case of patients with small aortic 
annuli, whose EOA is relatively small [12]. 
Aim of the study
The aim of the study was the evaluation of PPM inci-
dence in relation to the size of the prosthetic valves im-
planted in patients undergoing aortic valve replacement, 
as well as the perioperative assessment of the treatment 
results of PPM patients.
Material and methods
The study encompassed 92 patients undergoing sur-
gery, in whom mechanical St. Jude Medical valves of differ-
ent sizes were implanted. The studied group consisted of 
44 women (48%) and 48 men (52%), aged 21­74; mean age: 
53.6 years (±SD 9.8 years).
All patients were qualified for aortic valve replacement 
due to severe valvular stenosis of the left arterial orifice. 
The patients were monitored perioperatively until their dis-
charge from the hospital. The incidence of complications 
during the perioperative period was assessed, along with 
hemodynamic parameters after the implantation of pros-
thetic valves, by transthoracic echocardiography.
The patients were divided into 3 groups, based on 
the size of the implanted valves. The first group consisted 
of 15 patients who were implanted with valves of small 
aortic annulus diameter: 17 mm (3 patients) and 19 mm 
(12 pa tients). The second, largest group comprised 56 pa-
tients who were implanted with valves of medium aortic an-
nulus diameter: 21 mm (29 patients) and 23 mm (27 patients). 
The third group consisted of 21 patients, who were implanted 
with valves of large aortic annulus diameter: 25 mm (16 pa-
tients), 27 mm (2 patients), and 29 mm (3 patients).
Results
Clinically significant PPM was revealed in all patients 
with small aortic annuli. Severe PPM was revealed in 87% of 
patients, moderate in 13% (iEOA ranged from 0.38 cm2/m2 
to 0.8 cm2/m2; mean: 0.53 cm2/m2, ±SD 0.12 cm2/m2). 
The range of EOA was from 0.65 cm2 to 1.13 cm2 (mean: 
0.88 cm2 ±SD 0.13 cm2). The body surface area ranged from 
1.42 m2 to 2.05 m2 (mean: 1.70 m2 ±SD 0.17 m2). 
Among the patients with medium aortic annulus size, 
48.2% suffered from severe PPM, 44.6% suffered from moder-
ate PPM, and only 7.1% had no significant PPM (iEOA ranged 
from 0.4 cm2/m2 to 1 cm2/m2; mean: 0.68 cm2/m2 ±SD 
0.12 cm2/m2). The range of EOA was from 0.91 cm2 to 1.58 cm2 
(mean: 1.23 cm2 ±SD 0.16 cm2). The body surface area ranged 
from 1.51 m2 to 2.25 m2 (mean: 1.83 m2 ±SD 0.15 m2). 
Among the patients with large aortic annulus size, 9.5% 
suffered from severe PPM, 42.5% suffered from moderate 
PPM, and only 47.6% had no significant PPM (iEOA ranged 
from 0.61 cm2/m2 to 1.37 cm2/m2; mean: 0.88 cm2/m2 
±SD 0.2 cm2/m2). The range of EOA was from 1.35 cm2 to 
2.43 cm2 (mean: 1.69 cm2 ±SD 0.3 cm2). The body surface 
area ranged from 1.64 m2 to 2.20 m2 (mean: 1.94 m2 ±SD 
0.14 m2) (Fig. 1). 
Perioperative mortality of all patients undergoing surgery 
amounted to 5.4%. The largest percentage of perioperative 
deaths (20%) concerned the group with small aortic annuli. It 
appears significant that all 3 persons who died in this group 
were diagnosed with severe PPM (iEOA ≤ 0.65 cm2/m2). In 
the group with medium valves, the perioperative mortality 
was 1.8% (1 patient with severe PPM).
Mean and peak transvalvular gradient, as well as 
the change in ejection fraction during the early postopera-
tive period, were also assessed in relation to valve size.
The mean gradient through the aortic valve differed 
among the three groups during postoperative follow­up. 
The largest mean gradient was observed among the pa-
tients implanted with valves of small aortic annulus diam-
eter; it was 20.25 mm Hg (±SD = 7.37). In turn, in the pa-
tients with medium aortic annuli, the mean gradient was 
13.42 mm Hg (±SD = 5.94), and in the patients with large 
aortic annuli it was 11 mm Hg (±SD = 4). It appears impor-
Kardiochirurgia i Torakochirurgia Polska 2013; 10 (3) 201
CARDIAC SURGERy 
tant that the comparison between the mean gradient val-
ues of patients with small annuli and patients with medium 
(p = 0.009) and large annuli (p = 0.001) indicated, in both 
cases, statistically significant differences, while the com-
parison between the gradient values of patients with medi-
um and large annuli showed no such difference (p > 0.05). 
The peak transvalvular gradient among the patients with 
small, medium, and large valve annuli was, respectively: 
34.75 mm Hg (±SD = 11.34); 22.85 mm Hg (±SD = 9.25); 
18.18 mm Hg (±SD = 6.35). In all three groups, statistically 
significant differences were found. 
Changes in ejection fraction (EF) during the early post-
operative period were noted in all three groups. In the group 
of patients with small aortic annuli, EF decreased in 67% of 
patients; the mean EF change within the whole group was 
–7.58% (±SD = 10.59). In the group of patients with medium 
aortic annuli, EF decreased in more than 80% of patients; 
the mean EF change within the whole group was –10.68% 
(±SD = 11.22). Different results were noted in the group of 
patients with large aortic annuli, as the EF parameters in 
this group increased in 75% of patients, and the mean EF 
change was +11.55% (±SD = 11.97). These changes, how-
ever, are not statistically significant (p < 0.05).
The study also analyzed the characteristics of the im-
plemented valve size distribution in dependence on gender, 
age, and BMI.
Valves with small aortic annuli were most often used in 
women (93% women vs. 7% men), while valves with large 
aortic annuli were most frequently employed in men (90.5% 
men vs. 9.5% women). Valves with medium annuli were 
used in the same number of men (50%) and women (50%). 
The distribution was statistically significant (p < 0.05) (Fig. 2). 
No statistically significant changes were noted in any of 
the three groups with regard to patient age or BMI.
Conclusions
The occurrence of PPM among patients with small aor-
tic annuli was relatively more frequent (100% of iEOA re-
sults ≤ 0.85 cm2/m2) in comparison to other patients. 
Female patients are particularly susceptible to the oc-
currence of severe PPM and high transvalvular gradient 
values.
The occurrence of PPM appears to be a factor increasing 
the risk of perioperative death in the studied group.
Discussion
Decreasing the transvalvular gradient is the primary ob-
jective of aortic valve replacement. Surgeons always prefer 
implanting the largest possible prosthetic valve if the aor-
tic annulus is small, as it influences cardiac hemodynamic 
parameters and surgical treatment results. Nonetheless, 
the reduction of the gradient during the early postoperative 
period is often unsatisfactory due to the size of the em-
ployed valvular prosthesis [13, 17, 18]. Patient­prosthesis 
mismatch (PPM) is a frequently occurring problem which 
leads to the deterioration of hemodynamic function, re-
sults in a smaller postoperative reduction of left ventricular 
hypertrophy, increases the number of complications, and 
influences mortality.
Our study results provide evidence that the chance for 
PPM occurrence among patients with small aortic annuli (di-
ameters 17 mm and 19 mm) is higher (100% of iEOA results 
≤ 0.85 cm2/m2) than among patients in whom the diameter 
of the aortic annulus is more than 21 mm. Women constitute 
a group that is particularly susceptible to the occurrence of 
severe PPM, which results from the fact that the body sur-
face area and aortic annuli in women are significantly small-
er in comparison to men [19]. These findings are supported 
by earlier publications from other centers [20]. 
According to some reports, the occurrence of PPM, in 
particular severe PPM, appears to be a factor which in-
creases mortality during the early postoperative period [12]. 
In our study, almost all perioperative deaths occurred in pa-
tients with small aortic annuli, among whom 87% suffered 
from severe PPM.   
The implantation of 17 mm and 19 mm valves was in-
extricably associated with significantly higher postopera-
tive average and maximal transvalvular gradient values 
Fig. 1.
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in the study group. Not only can this lead to enhancing 
the abovementioned risks related to PPM, but it can also 
result in faster degeneration of the implanted valve, pro-
vided that a biological valve was employed [19]. 
The development of cardiac surgery allows for a sig-
nificant reduction of PPM, if not avoiding it altogether. 
This requires approaching each patient individually before 
the operation, calculating the desired EOA, and selecting 
appropriate valves for implantation. 
The slight change in EF observed during the early post-
operative period appears to be caused by the use of ex-
tracorporeal circulation during surgery. However, in­depth 
analysis of this phenomenon would require long-term EF 
observation, which was not the subject of this study.   
The possibility of symptomatic PPM occurrence in pa-
tients with small aortic annuli may be significantly reduced, 
owing to the rich variety of valve prostheses and the avail-
ability of supra-annular prostheses providing better hemo-
dynamic parameters.
Stentless valves may be used instead of mechanical 
prostheses and biological stent valves, as their different 
structure (no frame) allows for a larger orifice area, there-
fore providing better hemodynamic parameters [20­23]. 
Due to the larger iEOA of stentless valves, the risk of PPM 
occurrence is smaller than in the case of stent valves [24].
One of the more recent options is the use of suture-
less valves [25]; their structure and hemodynamic proper-
ties allow for a significant improvement of the EOA size 
and hemodynamic parameters, particularly with regard to 
the transvalvular gradient.
Other methods of avoiding PPM include valve implan-
tation with aortic annulus enlargement [22]. This proce-
dure should be considered if iEOA < 0.65 cm2/m2. Its aim 
is the implantation of a larger prosthesis and achieving 
the assumed index [26]. Unfortunately, the database of 
the Society of Thoracic Surgeons indicates that performing 
this procedure is associated with a significant risk increase, 
which is why it is rarely performed [STS database].
Employing homografts and autografts (the Ross proce-
dure) may also improve the hemodynamic parameters and 
reduce the possibility of PPM occurrence [27­30]. The use of 
these valves may, however, be constrained by their limited 
availability, technical difficulties, and greater complexity of 
the surgical procedure [23].
The results obtained in this study are supported by 
the conclusions of reports published by other centers. How-
ever, some reports indicate no PPM influence on periopera-
tive mortality [24]. Therefore, the results concerning mor-
tality should be interpreted with caution.
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